메뉴 건너뛰기




Volumn 8, Issue , 2016, Pages 157-164

Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: Evidence to date

Author keywords

Integrase inhibitor; Long acting antiretroviral therapy; Preexposure prophylaxis

Indexed keywords

CABOTEGRAVIR; DOLUTEGRAVIR; PLACEBO; RILPIVIRINE;

EID: 84992322809     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S97920     Document Type: Review
Times cited : (45)

References (57)
  • 1
    • 84876369710 scopus 로고    scopus 로고
    • Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT Trials compared to the general population
    • Rodger AJ, Lodwick R, Schecter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT Trials compared to the general population. AIDS. 2013;27(6):973-997.
    • (2013) AIDS , vol.27 , Issue.6 , pp. 973-997
    • Rodger, A.J.1    Lodwick, R.2    Schecter, M.3
  • 2
    • 84940530289 scopus 로고    scopus 로고
    • Initiation of antiretroviral therapy in early asymptomatic HIV infection
    • Lundgren JA, Babiker AG, Gordin F, et al; INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
    • (2015) N Engl J Med , vol.373 , Issue.9 , pp. 795-807
    • Lundgren, J.A.1    Babiker, A.G.2    Gordin, F.3
  • 3
    • 84954209401 scopus 로고    scopus 로고
    • Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial
    • McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53-60.
    • (2016) Lancet , vol.387 , Issue.10013 , pp. 53-60
    • McCormack, S.1    Dunn, D.T.2    Desai, M.3
  • 4
    • 84948822953 scopus 로고    scopus 로고
    • On-demand pre-exposure prophylaxis in men at high risk for HIV-1 infection
    • Molina JM, Capitant C, Spire B, et al; ANRS IPERGAY Study Group. On-demand pre-exposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237-2246.
    • (2015) N Engl J Med , vol.373 , Issue.23 , pp. 2237-2246
    • Molina, J.M.1    Capitant, C.2    Spire, B.3
  • 5
    • 78650549662 scopus 로고    scopus 로고
    • Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    • Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
    • (2010) N Engl J Med , vol.363 , pp. 2587-2599
    • Grant, R.M.1    Lama, J.R.2    Anderson, P.L.3
  • 6
    • 84864505868 scopus 로고    scopus 로고
    • Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    • Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
    • (2012) N Engl J Med , vol.367 , Issue.5 , pp. 399-410
    • Baeten, J.M.1    Donnell, D.2    Ndase, P.3
  • 7
    • 84864527306 scopus 로고    scopus 로고
    • Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana
    • Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-434.
    • (2012) N Engl J Med , vol.367 , Issue.5 , pp. 423-434
    • Thigpen, M.C.1    Kebaabetswe, P.M.2    Paxton, L.A.3
  • 8
    • 84864507852 scopus 로고    scopus 로고
    • Pre-exposure prophylaxis for HIV infection among African women
    • Van Damme L, Corneli A, Ahmed K, et al; FEM-PrEP Study Group. Pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-422.
    • (2012) N Engl J Med , vol.367 , Issue.5 , pp. 411-422
    • Van Damme, L.1    Corneli, A.2    Ahmed, K.3
  • 10
    • 84947938552 scopus 로고    scopus 로고
    • Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens
    • Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine (Baltimore). 2015;94(42):e1677.
    • (2015) Medicine (Baltimore) , vol.94 , Issue.42
    • Clay, P.G.1    Nag, S.2    Graham, C.M.3    Narayanan, S.4
  • 11
    • 84919458152 scopus 로고    scopus 로고
    • Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviralnaive adults infected with HIV-1: 96 week results from the NEAT001/ ANRS143 randomised non-inferiority trial
    • Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviralnaive adults infected with HIV-1: 96 week results from the NEAT001/ ANRS143 randomised non-inferiority trial. Lancet. 2014;384(9958): 1942-1951.
    • (2014) Lancet , vol.384 , Issue.9958 , pp. 1942-1951
    • Raffi, F.1    Babiker, A.G.2    Richert, L.3
  • 12
    • 80055028058 scopus 로고    scopus 로고
    • ACTG A5262 Team. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)
    • Taiwo B, Zheng L, Gallien S, et al; ACTG A5262 Team. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25(17):2113-2122.
    • (2011) AIDS , vol.25 , Issue.17 , pp. 2113-2122
    • Taiwo, B.1    Zheng, L.2    Gallien, S.3
  • 13
    • 84959203087 scopus 로고    scopus 로고
    • Dolutegravirlamivudine as initial therapy in HIV-infected, ARV naive patients: First results of the PADDLE trial
    • October 21-24, Barcelona, Spain
    • Figueroa M, Sued O, Patterson P, Gun A, Rolon M, Cahn P. Dolutegravirlamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial. In: 15th European AIDS Conference. October 21-24, 2015. Barcelona, Spain.
    • (2015) 15Th European AIDS Conference
    • Figueroa, M.1    Sued, O.2    Patterson, P.3    Gun, A.4    Rolon, M.5    Cahn, P.6
  • 14
    • 84962513459 scopus 로고    scopus 로고
    • The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: A randomised controlled trial of a protease inhibitor monotherapy strategy for longterm management of human immunodeficiency virus infection
    • Paton NI, Stohr W, Oddershede L, et al. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for longterm management of human immunodeficiency virus infection. Health Technol Assess. 2016;20(21):1-158.
    • (2016) Health Technol Assess , vol.20 , Issue.21 , pp. 1-158
    • Paton, N.I.1    Stohr, W.2    Oddershede, L.3
  • 15
    • 84898016347 scopus 로고    scopus 로고
    • Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
    • Solomon MM, Lama JR, Glidden DV, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851-859.
    • (2014) AIDS , vol.28 , Issue.6 , pp. 851-859
    • Solomon, M.M.1    Lama, J.R.2    Glidden, D.V.3
  • 16
  • 17
    • 84937215233 scopus 로고    scopus 로고
    • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials
    • Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987): 2606-2615.
    • (2015) Lancet , vol.385 , Issue.9987 , pp. 2606-2615
    • Sax, P.E.1    Wohl, D.2    Yin, M.T.3
  • 18
    • 84857772222 scopus 로고    scopus 로고
    • Long-acting antipsychotic medications
    • Baweja R, Sedky K, Lippman S. Long-acting antipsychotic medications. Curr Drug Targets. 2012;13(4):555-560.
    • (2012) Curr Drug Targets , vol.13 , Issue.4 , pp. 555-560
    • Baweja, R.1    Sedky, K.2    Lippman, S.3
  • 19
    • 40649085987 scopus 로고    scopus 로고
    • Hormonal contraceptive discontinuation patterns according to formulation: Investigation of associations in an administrative claims database
    • Murphy P, Brixner D. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. Contraception. 2008;77(4):257-263.
    • (2008) Contraception , vol.77 , Issue.4 , pp. 257-263
    • Murphy, P.1    Brixner, D.2
  • 20
    • 34548679894 scopus 로고    scopus 로고
    • Assessing regional differences in contraceptive disconti-nuation, failure and switching in Brazil
    • Leite IC, Gupta N. Assessing regional differences in contraceptive disconti-nuation, failure and switching in Brazil. Reprod Health. 2007;4:6.
    • (2007) Reprod Health , vol.4 , pp. 6
    • Leite, I.C.1    Gupta, N.2
  • 21
    • 84992385561 scopus 로고    scopus 로고
    • Understanding pain and anxiety experienced around long-acting injectable PrEP
    • February, Boston, Massachusetts Abstract number 881
    • Meyers K, Rodriguez K, Markowitz M, Golub SA. Understanding pain and anxiety experienced around long-acting injectable PrEP. In: CROI, February 2016. Boston, Massachusetts Abstract number 881.
    • (2016) CROI
    • Meyers, K.1    Rodriguez, K.2    Markowitz, M.3    Golub, S.A.4
  • 22
    • 84886473877 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor
    • Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14(5):192-203.
    • (2013) HIV Clin Trials , vol.14 , Issue.5 , pp. 192-203
    • Spreen, W.1    Min, S.2    Ford, S.L.3
  • 23
    • 84992313756 scopus 로고    scopus 로고
    • webpage on the Internet, updated on eMC July 1, Accessed June 8
    • EMC [webpage on the Internet]. Isentress 400 mg Film-coated Tablets-summary of product characteristics (SPC). [updated on eMC July 1, 2015]. Available from: http://www.medicines.org.uk/emc/ medicine/20484/SPC/. Accessed June 8, 2016.
    • (2015) Isentress 400 Mg Film-Coated Tablets-Summary of Product Characteristics (SPC)
  • 25
  • 26
    • 84992357039 scopus 로고    scopus 로고
    • European AIDS Clinical Society Guidelines Version 8.0 English October 2015, Accessed 8 June
    • EACS. European AIDS Clinical Society Guidelines Version 8.0 English October 2015. Available from: http://www.eacsociety.org/files/ guidelines_8.0-english.pdf. Accessed 8 June 2016.
    • (2016)
  • 27
    • 84904568743 scopus 로고    scopus 로고
    • Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel
    • Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):410-425.
    • (2014) JAMA , vol.312 , Issue.4 , pp. 410-425
    • Gunthard, H.F.1    Aberg, J.A.2    Eron, J.J.3
  • 29
    • 0035876041 scopus 로고    scopus 로고
    • Non-adherence to highly active antiretroviral therapy predicts progression to AIDS
    • Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181-1183.
    • (2001) AIDS , vol.15 , Issue.9 , pp. 1181-1183
    • Bangsberg, D.R.1    Perry, S.2    Charlebois, E.D.3
  • 31
    • 84923701359 scopus 로고    scopus 로고
    • GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1
    • Karmon SL, Mohri H, Spreen W, Markowitz M. GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1. J Acquir Immune Defic Syndr. 2015;68(3):e39-e41.
    • (2015) J Acquir Immune Defic Syndr , vol.68 , Issue.3 , pp. e39-e41
    • Karmon, S.L.1    Mohri, H.2    Spreen, W.3    Markowitz, M.4
  • 32
    • 84920189964 scopus 로고    scopus 로고
    • Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection
    • Yoshinaga T, Kobayashi M, Seki T, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015;59(1):397-406.
    • (2015) Antimicrob Agents Chemother , vol.59 , Issue.1 , pp. 397-406
    • Yoshinaga, T.1    Kobayashi, M.2    Seki, T.3
  • 33
    • 84925557632 scopus 로고    scopus 로고
    • GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects
    • Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr. 2014;67(5):481-486.
    • (2014) J Acquir Immune Defic Syndr , vol.67 , Issue.5 , pp. 481-486
    • Spreen, W.1    Ford, S.L.2    Chen, S.3
  • 34
    • 84921020451 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults
    • Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr. 2014;67(5):487-492.
    • (2014) J Acquir Immune Defic Syndr , vol.67 , Issue.5 , pp. 487-492
    • Spreen, W.1    Williams, P.2    Margolis, D.3
  • 36
    • 84987791972 scopus 로고    scopus 로고
    • ViiV Healthcare Ltd, Accessed July 1
    • ViiV Healthcare Ltd. Dolutegravir Summary of Product Characteristics. ViiV Healthcare Ltd; 2015. Available from: https://www.medicines.org.uk/emc/medicine/28545isdolutegravirspc. Accessed July 1, 2016.
    • (2015) Dolutegravir Summary of Product Characteristics
  • 37
    • 84958121340 scopus 로고    scopus 로고
    • Drug interaction profile of the HIV integrase inhibitor cabotegravir: Assessment from in vitro studies and a clinical investigation with midazolam
    • Reese MJ, Bowers GD, Humphreys JE, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2016;46(5):445-456.
    • (2016) Xenobiotica , vol.46 , Issue.5 , pp. 445-456
    • Reese, M.J.1    Bowers, G.D.2    Humphreys, J.E.3
  • 38
    • 84872050289 scopus 로고    scopus 로고
    • Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK 1265744
    • Ford SL, Gould E, Chen S, et al. Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK 1265744. Antimicrob Agents Chemother. 2013;57(1):277-280.
    • (2013) Antimicrob Agents Chemother , vol.57 , Issue.1 , pp. 277-280
    • Ford, S.L.1    Gould, E.2    Chen, S.3
  • 39
    • 84992353740 scopus 로고    scopus 로고
    • Phase 1, Single-Center, Open-Label, Fixed Sequence Cross-Over Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects, Accessed July 1
    • Glaxo Smith Kline PLC. Phase 1, Single-Center, Open-Label, Fixed Sequence Cross-Over Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects. Available from: http://www.gsk-clinicalstudyregister.com/files2/gsk-117010-clinical-study-result-summary.pdf. Accessed July 1, 2016.
    • (2016)
    • Glaxo Smith Kline, P.L.C.1
  • 41
    • 84885934539 scopus 로고    scopus 로고
    • Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK 1265744
    • Ford SL, Gould E, Chen S, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK 1265744. Antimicrob Agents Chemother. 2013;57(11):5472-5477.
    • (2013) Antimicrob Agents Chemother , vol.57 , Issue.11 , pp. 5472-5477
    • Ford, S.L.1    Gould, E.2    Chen, S.3
  • 42
    • 84921044609 scopus 로고    scopus 로고
    • The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge
    • Radzio J, Spreen W, Yueh YL, et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med. 2015;7(270):270ra5.
    • (2015) Sci Transl Med , vol.7 , Issue.270
    • Radzio, J.1    Spreen, W.2    Yueh, Y.L.3
  • 43
    • 85017409155 scopus 로고    scopus 로고
    • Eclair: Phase 2A safety and PK study of Cabotegravir LA in HIV-uninfected men
    • February, Boston, Massachusetts Abstract number 106
    • Markowitz M, Frank I, Grant R, et al. Eclair: phase 2A safety and PK study of Cabotegravir LA in HIV-uninfected men. In: CROI, February 2016. Boston, Massachusetts Abstract number 106.
    • (2016) CROI
    • Markowitz, M.1    Frank, I.2    Grant, R.3
  • 44
    • 84896769378 scopus 로고    scopus 로고
    • Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus
    • Andrews CD, Spreen WR, Mohri H, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151-1154.
    • (2014) Science , vol.343 , Issue.6175 , pp. 1151-1154
    • Andrews, C.D.1    Spreen, W.R.2    Mohri, H.3
  • 45
    • 84992385550 scopus 로고    scopus 로고
    • Clinicaltrials.gov. Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men, Accessed July 1
    • National Institutes of Health. Clinicaltrials.gov. Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men. Available from: https://clinicaltrials.gov/show/NCT02720094. Accessed July 1, 2016.
    • (2016)
  • 46
    • 19944428117 scopus 로고    scopus 로고
    • Multiple vaginal exposures to low doses of R5 simian-human immuno-deficiency virus: Strategy to study HIV preclinical interventions in nonhuman primates
    • Otten RA, Adams DR, Kim CN, et al. Multiple vaginal exposures to low doses of R5 simian-human immuno-deficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis. 2005;191(2):164-173.
    • (2005) J Infect Dis , vol.191 , Issue.2 , pp. 164-173
    • Otten, R.A.1    Adams, D.R.2    Kim, C.N.3
  • 47
    • 84870748389 scopus 로고    scopus 로고
    • Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen
    • Radzio J, Aung W, Holder A, et al. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One. 2012;7(12):e50632.
    • (2012) Plos One , vol.7 , Issue.12
    • Radzio, J.1    Aung, W.2    Holder, A.3
  • 48
    • 0023033053 scopus 로고
    • Man versus beast: Pharmacokinetic scaling in mammals
    • Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci. 1986;75(11):1028-1040.
    • (1986) J Pharm Sci , vol.75 , Issue.11 , pp. 1028-1040
    • Mordenti, J.1
  • 49
    • 84902294966 scopus 로고    scopus 로고
    • Physiologic doses of depot-medroxypro-gesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques
    • Radzio J, Hanley K, Mitchell J, et al. Physiologic doses of depot-medroxypro-gesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques. AIDS. 2014; 28(10):1431-1439.
    • (2014) AIDS , vol.28 , Issue.10 , pp. 1431-1439
    • Radzio, J.1    Hanley, K.2    Mitchell, J.3
  • 50
    • 84992391209 scopus 로고    scopus 로고
    • Cabotegravir long-acting injection protects macaques against intravenous challenge
    • February, Boston, Massachusetts Abstract number
    • Andrews CD, St Bernard L, Poon A, et al. Cabotegravir long-acting injection protects macaques against intravenous challenge. In: CROI, February 2016. Boston, Massachusetts Abstract number 105.
    • (2016) CROI , pp. 105
    • Andrews, C.D.1    St Bernard, L.2    Poon, A.3
  • 51
    • 85017409155 scopus 로고    scopus 로고
    • ECLAIR: Phase 2A safety and PK study of Cabotegravir LA in HIV-uninfected men
    • February, Boston, Massachusetts Abstract number
    • Markowitz M, Frank I, Grant R, et al. ECLAIR: phase 2A safety and PK study of Cabotegravir LA in HIV-uninfected men. In: CROI, February 2016. Boston, Massachusetts Abstract number 106.
    • (2016) CROI , pp. 106
    • Markowitz, M.1    Frank, I.2    Grant, R.3
  • 52
    • 84992313745 scopus 로고    scopus 로고
    • webpage on the Internet, GSK1265744, in HIV-uninfected men and women. Study protocol final version 2.0. IND # 122744. DAIDS Document ID: 11964, Accessed June 21
    • HPTN 077 [webpage on the Internet]. A Phase IIa study to evaluate the safety, tolerability and pharma-cokinetics of the investigational injectable HIV integrase inhibitor, GSK1265744, in HIV-uninfected men and women. Study protocol final version 2.0. IND # 122744. DAIDS Document ID: 11964. Available from: https://www.hptn.org/research/studies/153. Accessed June 21, 2016.
    • (2016) A Phase Iia Study to Evaluate the Safety, Tolerability and Pharma-Cokinetics of the Investigational Injectable HIV Integrase Inhibitor
  • 53
    • 84942191100 scopus 로고    scopus 로고
    • LAI116482 Study Team. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): A randomised, phase 2b, dose-ranging trial
    • Margolis DA, Brinson CC, Smith GH, et al; LAI116482 Study Team. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15(10): 1145-1155.
    • (2015) Lancet Infect Dis , vol.15 , Issue.10 , pp. 1145-1155
    • Margolis, D.A.1    Brinson, C.C.2    Smith, G.H.3
  • 54
    • 84879874721 scopus 로고    scopus 로고
    • Dolutegravir in antiretroviralnaive adults with HIV-1: 96 week results from a randomized doseranging study
    • Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviralnaive adults with HIV-1: 96 week results from a randomized doseranging study. AIDS. 2013;27(11):1771-1778.
    • (2013) AIDS , vol.27 , Issue.11 , pp. 1771-1778
    • Stellbrink, H.J.1    Reynes, J.2    Lazzarin, A.3
  • 55
    • 84887052771 scopus 로고    scopus 로고
    • Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection
    • Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-1818.
    • (2013) N Engl J Med , vol.369 , Issue.19 , pp. 1807-1818
    • Walmsley, S.L.1    Antela, A.2    Clumeck, N.3
  • 56
    • 84988948359 scopus 로고    scopus 로고
    • Cabotegravir + Rilpivirine as long acting maintenance therapy: LATTE-2 week 32 results
    • February, Boston, Massachusetts. Abstract Number: 31LB
    • Margolis DA, Gonazalez-Garcia J, Stellbrink HJ, et al. Cabotegravir + Rilpivirine as long acting maintenance therapy: LATTE-2 week 32 results. In: CROI, February 2016 Boston, Massachusetts. Abstract Number: 31LB.
    • (2016) CROI
    • Margolis, D.A.1    Gonazalez-Garcia, J.2    Stellbrink, H.J.3
  • 57
    • 84998571678 scopus 로고    scopus 로고
    • Tolerability and acceptability of cabotegravir LA injection: Results from ECLAIR study
    • February, Boston, Massachusetts Abstract number 471
    • Murray M, Markowitz M, Frank I, et al. Tolerability and acceptability of cabotegravir LA injection: results from ECLAIR study. In: CROI, February 2016. Boston, Massachusetts Abstract number 471.
    • (2016) CROI
    • Murray, M.1    Markowitz, M.2    Frank, I.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.